Covered stent with controlled therapeutic agent diffusion

• US 20060058870A1
• Filed: 09/14/2004
• Published: 03/16/2006
• Est. Priority Date: 09/14/2004
• Status: Active Grant

• Current Assignee: LeMaitre Vascular, Incorporated
• Original Assignee: Vascular Architects Incorporated
• Inventors: Iki, Kobi, Tsuruda, Marshall
• Granted Patent: US 7,063,720 B2
• Time in Patent Office: Days
• US Class Current: 623/1.440
• CPC Class Codes: A61F 2/88 the wire-like elements formed as helical or spiral coils forming a net-like or mesh-like structure A61F2/90
• CPC Class Codes: A61F 2/91 made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
• CPC Class Codes: A61F 2250/0068 the pharmaceutical product being in a reservoir

Abstract

A covered stent includes a generally tubular stent body having inner and outer stent body surfaces. A sleeve of porous material encloses the stent body and has inner and outer portions opposed to the inner and outer stent body surfaces. A therapeutic agent is located along the stent body, the agent being diffusible through the material. A diffusion barrier is located between the inner material portion and the agent along the stent. The diffusion barrier prevents passage of at least a significant amount the agent through the inner portion of the sleeve of porous material. A diffusion restrictor is located between the outer portion of the sleeve of porous material and the agent along the stent. The diffusion restrictor permits passage of the agent through the inner material portion at a therapeutic level.

Claims

1. A covered stent comprising:

a generally tubular stent body having inner and outer stent body surfaces;

a sleeve of porous material enclosing the stent body, the sleeve of material having inner and outer material portions opposed to the inner and outer stent body surfaces;

a therapeutic agent along the stent body, the agent being diffusible through the sleeve of porous material;

a diffusion restrictor between the outer material portion and the agent along the stent, said diffusion restrictor permitting passage of the agent through the inner material portion at a first, therapeutic rate; and

a diffusion barrier between the inner material portion and the agent along the stent, said diffusion barrier preventing passage of the agent through the inner material portion at at most a second rate, the second rate being less than the first rate.

2. The covered stent according to claim 1 wherein the second rate is at least 50% less than the first rate.

3. The covered stent according to claim 1 wherein the stent body extends along a generally helical path.

4. The covered stent according to claim 3 wherein the sleeve of porous material extends along said generally helical path to define a covered stent structure having a length, the covered stent structure having turns, the covered stent structure defining a generally helical gap between the turns along at least substantially the entire length of the covered stent structure.

5. The covered stent according to claim 1 further comprising a silicone carrier carrying the agent.

6. The covered stent according to claim 1 wherein the agent comprises a hydrophilic agent.

7. The covered stent according to claim 1 wherein the agent comprises a hydrophilic anti-restenotic agent.

8. The covered stent according to claim 7 wherein the agent comprises at least one of Sodium Nitroprusside, L-Arginine and Poly L-Arginine.

9. The covered stent according to claim 1 wherein the agent adheres to the stent body.

10. The covered stent according to claim 9 wherein the diffusion barrier is applied onto the agent adhering to the stent body.

11. The covered stent according to claim 9 wherein the diffusion restrictor is applied onto the agent adhering to the stent body.

12. The covered stent according to claim 9 wherein the diffusion restrictor and the diffusion barrier are made of the same diffusion material.

13. The covered stent according to claim 12 wherein the diffusion material comprises Parylene.

14. The covered stent according to claim 13 wherein the diffusion barrier is greater than about 3.5 micrometers thick and the diffusion restrictor is less than about 2.5 micrometers thick.

15. The covered stent according to claim 13 wherein the diffusion barrier and the diffusion restrictor have different thicknesses with the diffusion barrier being about 3-5 micrometers thick and the diffusion restrictor being about 1-3 micrometers thick.

16. The covered stent according to claim 13 wherein the diffusion barrier comprises a substantially non-porous vapor-deposited layer of Parylene and the diffusion restrictor comprises a micro-porous vapor-deposited layer of Parylene.

17. A covered stent comprising:

a generally tubular stent body having an inner and outer stent body surfaces;

a sleeve of porous material enclosing the stent body, the sleeve of material having inner and outer material portions opposed to the inner and outer stent body surfaces;

a hydrophilic anti-restenotic therapeutic agent/silicone carrier matrix adhering to the stent body, the agent being diffusible through the sleeve of porous material;

a diffusion restrictor applied onto the therapeutic agent/silicone carrier matrix along the stent, said diffusion restrictor permitting passage of the agent through the inner material portion at a first, therapeutic rate;

a diffusion barrier applied onto the therapeutic agent/silicone carrier matrix along the stent, said diffusion barrier preventing passage of the agent through the inner material portion at at most a second rate, the second rate being less than the first rate; and

the diffusion restrictor and the diffuser barrier comprising Parylene.

18. The covered stent according to claim 17 wherein:

the diffusion barrier is greater than about 3.5 micrometers thick;

the diffusion restrictor is less than about 2.5 micrometers thick;

the stent body extends along a generally helical path;

the sleeve of the porous material extends along said generally helical path to define a covered stent structure having a length, the covered stent structure having turns, the covered stent structure defining a generally helical gap between the turns along at least substantially the entire length of the covered stent structure; and

the agent comprises at least one of Sodium Nitroprusside, L-Arginine or Poly L-Arginine.

19. The covered stent according to claim 17 wherein the diffusion barrier comprises a substantially non-porous vapor-deposited layer of Parylene and the diffusion restrictor comprises a micro-porous vapor-deposited layer of Parylene.

20. The covered stent according to claim 17 wherein the second rate is at least 50% less than the first rate.